Search results

711 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter
Quality standards Remove Quality standards filter

Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

In development [GID-TAG424] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - bortezomib (consolidation therapy) [ID529]

In development [GID-TAG320] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

In development [GID-TAG435] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Generalised anxiety disorder - quetiapine [ID347]

In development [GID-TAG421] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer - capecitabine [ID389]

In development [GID-TAG394] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (advanced and metastatic) - temozolomide [ID316]

In development [GID-TAG401] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

In development [GID-TAG406] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Radiofrequency ablation for palliation of painful spinal metastases

In development [GID-IPG10158] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Magnetic resonance therapy for knee osteoarthritis

In development [GID-IPG10159] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Endobronchial vagal nerve ablation for chronic obstructive pulmonary disease

In development [GID-IPG10160] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)

In development [GID-IPG10161] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intramedullary distraction for upper limb lengthening

In development [GID-IPG10163] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Hysteroscopic morcellation of uterine leiomyomas (fibroids)

In development [GID-IPG10165] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Laparoscopic renal denervation

In development [GID-IPG10166] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Microwave ablation for treating primary lung cancer and metastases in the lung

In development [GID-IPG10181] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife

In development [GID-IPG10179] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Intramedullary distraction for lower limb lengthening

In development [GID-IPG10180] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

Proposed [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Baloxavir marboxil for treating influenza [ID1537]

In development [GID-TA10559] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

In development [GID-TA10544] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

In development [GID-TA10562] Expected publication date: 03 March 2021

Type

Technology appraisal guidance

Status

In development
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

In development [GID-TA10387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]

Proposed [GID-TA10766] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

Proposed [GID-TA10767] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

Proposed [GID-TA10768] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]

Proposed [GID-TA10770] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating active ankylosing spondylitis [ID3865]

Proposed [GID-TA10771] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]

Proposed [GID-TA10772] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

Proposed [GID-TA10773] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Proposed [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Proposed [GID-TA10774] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

Proposed [GID-TA10775] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 14 April 2021

Type

Technology appraisal guidance

Status

In development
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Proposed [GID-TA10776] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Proposed [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]

Proposed [GID-TA10778] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed